These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 31997802)

  • 61. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms.
    Tenenbaum L; Humbert-Claude M
    Front Neuroanat; 2017; 11():29. PubMed ID: 28442998
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bone morphogenetic proteins.
    Chen D; Zhao M; Mundy GR
    Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
    Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT
    Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands.
    Kirik D; Cederfjäll E; Halliday G; Petersén Å
    Neurobiol Dis; 2017 Jan; 97(Pt B):179-188. PubMed ID: 27616425
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease.
    Shadfar S; Kim YG; Katila N; Neupane S; Ojha U; Bhurtel S; Srivastav S; Jeong GS; Park PH; Hong JT; Choi DY
    Mol Neurobiol; 2018 Jan; 55(1):554-566. PubMed ID: 27975170
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The yin and yang of α-synuclein-associated epigenetics in Parkinson's disease.
    Pavlou MAS; Pinho R; Paiva I; Outeiro TF
    Brain; 2017 Apr; 140(4):878-886. PubMed ID: 27585855
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 70. TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.
    Nam JH; Park ES; Won SY; Lee YA; Kim KI; Jeong JY; Baek JY; Cho EJ; Jin M; Chung YC; Lee BD; Kim SH; Kim EG; Byun K; Lee B; Woo DH; Lee CJ; Kim SR; Bok E; Kim YS; Ahn TB; Ko HW; Brahmachari S; Pletinkova O; Troconso JC; Dawson VL; Dawson TM; Jin BK
    Brain; 2015 Dec; 138(Pt 12):3610-22. PubMed ID: 26490328
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rotenone and elevated extracellular potassium concentration induce cell-specific fibrillation of α-synuclein in axons of cholinergic enteric neurons in the guinea-pig ileum.
    Sharrad DF; Chen BN; Gai WP; Vaikath N; El-Agnaf OM; Brookes SJ
    Neurogastroenterol Motil; 2017 Apr; 29(4):. PubMed ID: 27997067
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intracerebroventricularly-administered 1-methyl-4-phenylpyridinium ion and brain-derived neurotrophic factor affect catecholaminergic nerve terminals and neurogenesis in the hippocampus, striatum and substantia nigra.
    Chen JF; Wang M; Zhuang YH; Behnisch T
    Neural Regen Res; 2018 Apr; 13(4):717-726. PubMed ID: 29722326
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons.
    Iwakura Y; Piao YS; Mizuno M; Takei N; Kakita A; Takahashi H; Nawa H
    J Neurochem; 2005 May; 93(4):974-83. PubMed ID: 15857400
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Gangliosides, α-Synuclein, and Parkinson's Disease.
    Ledeen RW; Wu G
    Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease.
    Bartus RT; Brown L; Wilson A; Kruegel B; Siffert J; Johnson EM; Kordower JH; Herzog CD
    Neurobiol Dis; 2011 Oct; 44(1):38-52. PubMed ID: 21704161
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson's disease.
    Hernandez-Chan NG; Bannon MJ; Orozco-Barrios CE; Escobedo L; Zamudio S; De la Cruz F; Gongora-Alfaro JL; Armendáriz-Borunda J; Reyes-Corona D; Espadas-Alvarez AJ; Flores-Martínez YM; Ayala-Davila J; Hernandez-Gutierrez ME; Pavón L; García-Villegas R; Nadella R; Martinez-Fong D
    J Biomed Sci; 2015 Jul; 22(1):59. PubMed ID: 26198255
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy.
    Domanskyi A; Saarma M; Airavaara M
    Hum Gene Ther; 2015 Aug; 26(8):550-9. PubMed ID: 26176331
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.
    Hegarty SV; Sullivan AM; O'Keeffe GW
    Mol Neurobiol; 2014 Oct; 50(2):559-73. PubMed ID: 24504901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.